DR. LAURENCE FELDMEYER (Orcid ID : 0000-0002-4858-5525)

DR. HELMUT BELTRAMINELLI (Orcid ID : 0000-0002-8179-1793)

PROF. LUCA BORRADORI (Orcid ID : 0000-0003-0424-6297)

Article type : Letter to Editor

Letter to the Editor

Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms

Running head: Pemphigoid, lichenoid reaction and immune checkpoint inhibitors

M. Fässler¹, A. Rammlmair¹, L. Feldmeyer¹, V. G. A. Suter², A. Gloor¹, M. Horn³, K. Deml¹, H. Beltraminelli¹, L. Borradori¹

¹ Department of Dermatology, Inselspital, Bern University Hospital, CH-3010 Bern, Switzerland

² Department of Oral Surgery and Stomatology, School of Dental Medicine, University of Bern, CH-3010 Bern, Switzerland

³ Department of Laboratory Medicine, Inselspital, Bern University Hospital, CH-3010 Bern, Switzerland

Corresponding author:

Luca Borradori M.D.

Department of Dermatology, Inselspital, Bern University Hospital,

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/JDV.16036](https://doi.org/10.1111/JDV.16036)

This article is protected by copyright. All rights reserved

CH-3010 Bern, Switzerland
Telephone: +41 31 6322271
Email: luca.borradori@insel.ch

Funding sources: This article has no funding source

IRB approval status: Not applicable

Prior presentation: None

Manuscript word count: 609 words

References: 10

Figure: 1

Table: 1

Conflict of interest: None

Keywords: Mucous membrane pemphigoid, pemphigoid, lichen, lichenoid reaction, immune checkpoint inhibitors, anti-PD-1 antibodies, drug-triggered pemphigoid

Immune checkpoint inhibitor (ICI) therapy has demonstrated impressive antitumor activity.¹ However, it causes adverse effects, including lichenoid reactions.^{1,2} Cases of ICI-triggered bullous pemphigoid (BP) and anecdotally mucous membrane pemphigoid (MMP) have also been reported.²⁻⁶ We describe two new cases of pembrolizumab-triggered MMP, one of which was associated with cutaneous lichenoid lesions.

Case 1. A 77-year-old man presented with metastatic melanoma for which he received pembrolizumab and stereotactic radiation therapy (**Table 1**). Six months later he developed pruritic skin lesions followed by painful oral lesions. Examination revealed lichenoid papules on the limbs as well as oral erosions of the cheek mucosa and gingiva (**Fig. 1**). Light microscopy studies of skin and mucosal biopsy specimens showed a lichenoid inflammation with apoptotic basal keratinocytes and subepithelial cleft formation with eosinophils, respectively. Immunopathological studies confirmed the diagnosis of

MMP. The patient was given doxycycline and topical corticosteroids with partial remission of oral lesions, while the lichenoid lesions resolved. Five-month after ICI cessation, his condition remained unchanged.

Case 2. An 81-year-old woman was given pembrolizumab for metastatic melanoma. Six months later, she presented with painful oral lesions of the buccal and gingival mucosa as well as isolated erosions on her face and scalp (**Fig. 1**). Light microscopy studies of a buccal mucosa were consistent with MMP. Immunopathological studies were positive (**Table 1**). The patient was given doxycycline and topical corticosteroids. During the 12-month follow up, despite ICI termination, she still had relapsing oral lesions, while skin lesions resolved.

MMP is an autoimmune subepithelial blistering disorder characterized by involvement of mucosal surfaces, a tendency for scarring and a variable reactivity profile of patients' autoantibodies.³ Skin lesions, which are found in 25% of cases, are often limited and confined to the face and scalp, as in our second patient.³ Only three cases of MMP linked to ICI therapy have been described so far: while two cases had only mild oral involvement as in our two observations, the third case developed severe stenosis of the larynx.⁴⁻⁶ Our first case was striking, since he developed oral MMP in combination with lichenoid cutaneous lesions. Lichenoid reactions with rarely mucosal involvement are observed in approximately 25% of cases during ICI therapy, but BP has also been increasingly reported.^{2,5} In a review of 27 ICB-triggered BP cases, the median age was 68 years.^{2,5} The interval between start of ICIs and BP onset was highly variable with a median of 6 months, as in our cases. The disease may however also occur several months after ICB discontinuation.⁵

ICI therapy with anti-programmed death-1/ programmed death-ligand 1 results in a breakdown of tolerance, reduces activity of regulatory T cells (Tregs), and activates B cells and autoreactive T cells.¹ *Murphy* mice characterized by a Tregs dysfunction develop both a lichenoid interface dermatitis and an autoantibody response to BP180 and BP230.⁷ Hence, Tregs blockade may result in both autoreactive cellular and humoral response to the same antigenic targets of the epidermal and epithelial BMZ. Lichen planus (LP) patients have also been found to have an autoreactive T cells against BP180, the major target antigen of BP and MMP.^{3,8} These findings may explain the

phenotype observed in our first patient showing concomitantly a cutaneous lichenoid and an oral subepithelial blistering dermatosis and further raise the question about the nosologic relationship of our first case with *lichen planus pemphigoides* as well as a new subtype of MMP with oral lichen features.^{3,9} Hence, autoimmune blistering and lichenoid dermatoses, as also observed in in paraneoplastic pemphigus, seem to share an immune response directed against the same target antigens, explaining their potential clinical presentations overlap.¹⁰ The factors responsible for the final clinical phenotypes remains to be elucidated.

Acknowledgments: The authors are thankful to Mrs M. Elias and Mrs A. von Gunten for their photography work.

Abbreviations:

ICB, immune checkpoint blockade

BP, bullous pemphigoid

MMP, mucous membrane pemphigoid

BMZ, basement membrane zone

CR, complete remission

PR, partial remission

Tregs, regulatory T cells

DIF, direct immunofluorescence microscopy

IIF, indirect immunofluorescence using NaCl-separated normal human skin

References

1. Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. *Annu Rev Immunol* 2016; **34**:539-573.
2. Wang SJ, Carlos G, Wakade D, *et al.* Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. *J Am Acad Dermatol* 2016;**74**:455-461.
3. Bernard P, Borradori L. Pemphigoid group. In: Bologna JL, Schaffer JV, Cerroni L, eds. *Dermatology*. Elsevier Limited. 2018: 510-526.
4. Haug V, Behle V, Benoit S, *et al.* Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma. *Br J Dermatol* 2018;**179**:993-994.
5. Zumelzu C, Alexandre M, Le Roux C, *et al.* Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1/ programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature. *Front Med (Lausanne)* 2018;**5**:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.
6. Bezinelli LM, Eduardo FP, Migliorati CA *et al.* A severe, refractory case of mucous membrane pemphigoid after treatment with pembrolizumab: brief communication *J Immunother.* 2019; Jun 25. doi: 10.1097/CJI.0000000000000280
7. Muramatsu K, Ujiie H, Kobayashi I *et al.* Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects. *J Allergy Clin Immunol* 2018; **142**: 1818–1830.e6.
8. Schmidt T, Solimani F, Pollmann R *et al.* Th1/Th17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in lichen planus. *J Allergy Clin Immunol* 2018; **142**: 669–672.
9. M. Benzaquen M, Suter VGA, Gschwend M, *et al.* Mucous membrane pemphigoid of the oral lichen type: a retrospective analysis of 16 cases. *J Eur Acad Dermatol Venereol* 2019; **33**, e187–e229
10. Nguyen VT, Ndoeye A, Bassler KD *et al.* Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic

autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus.
Arch Dermatol 2001; **137**: 193-206.

Legend

Figure 1. Clinicopathological features of the patients. Case 1 with (a) isolated violaceous colored lichenoid maculopapular lesions on the upper limbs. (b) Light microscopy studies of a skin biopsy specimen show an interface dermatitis, apoptotic keratinocytes and a lymphocytic infiltrate in the upper dermis with some eosinophils. (c) Erythema and erosions of the gingival margins. (d) Light microscopy studies of an oral biopsy specimen demonstrate subepithelial blister formation and inflammation with eosinophils. (e) Direct immunofluorescence microscopy shows linear IgG deposits along the epithelial basement membrane zone. Case 2 (f) with desquamative gingivitis with edema, erythema and erosions. Sloughing of the mucosa with shaggy margins.

Table 1. Demographics and characteristics of reported cases of mucous membrane pemphigoid (MMP) after immune checkpoint inhibitor (ICI) therapy

Patients Age, sex (reference)	Malignancy	Clinical features	Immunopathology	Management of malignancy	Onset of MMP after starting ICI	Therapy and course of MMP
62 year, male (4)	Metastatic Merkel cell carcinoma	Oral blisters and erosions (tongue, buccal mucosa) No skin involvement	Linear deposits of C3 along the epithelial BMZ ELISA-BP180, 23.6 U/mL IIF, epidermal staining IB, positive for BP180 (IgG, IgA)	Pembrolizumab, (Keytruda®), 2 mg/kg, every 3 weeks	13 weeks after initiation ICI then stopped	Oral doxycycline Topical steroids PR on therapy
83 years, Female (5)	Metastatic melanoma	Oral erosions, gingivitis,pseudo- lichenoid lesions No skin involvement	Linear deposits of IgG and C3 along the epithelial BMZ IIF studies, negative ELISA-BP180, negative ELISA-BP230, negative IIE, positive	Pembrolizumab 2 mg/kg, every 3 weeks	66 weeks (24 weeks after ICI stop)	Oral doxycycline Corticosteroid oral washes CR off therapy after three months
61 years, female (6)	Metastatic ovarian adenocarcinoma	Oral erosions and gingivitis Conjunctivitis, dysphagia, nasal and pharyngeal erosions, and laryngeal stenosis	Linear deposits of IgG and C3 along the epithelial BMZ IIF, epidermal staining	Carboplatin and Paclitaxel, then Pembrolizumab 2 mg/kg. stopped after 5 cycles (tumor progression) Start of doxorubicin	6 weeks after ICI initiation	Oral prednisone Infliximab Methylprednisolone IVIg Rituximab PR on therapy Death due to sepsis
78 years, male Case 1 <i>Present report</i>	Malignant melanoma with brain and pulmonary metastases	Pruritic cutaneous lichenoid lesions Oral cheek erosions, desquamative gingivitis	Linear deposits of IgG along the epithelial and epidermal BMZ (with n-serration pattern) ELISA-BP180, 18.3 U/ml IIF, epidermal staining	Stereotactic radiation and pembrolizumab, 2 mg/kg, every 3 for 38 cycles ICI stopped after CR of melanoma	24 weeks after initiation	Oral doxycycline Oral nicotinamide Topical corticosteroids PR on minimal therapy

82 years, female Case 2 <i>Present report</i>	Malignant melanoma with skin metastases	Oral blisters erosions of cheek mucosa, soft palate and desquamative gingivitis Single cutaneous blisters	Linear deposits of IgG /C3 along the epithelial and epidermal BMZ (with n- serration pattern) ELISA-BP180, negative ELISA-BP230, negative	Pembrolizumab 3 weeks, for 16 cycles ICI stopped after CR of melanoma	24 weeks after initiation	Oral doxycycline Corticosteroids oral washes Topical corticosteroids PR on minimal therapy
--	---	---	--	---	------------------------------	--

BMZ, basement membrane zone; IIF, indirect immunofluorescence microscopy using NaCl-separated normal human skin; IIE, immunoelectron microscopy; CR and PR, complete response and partial response, respectively, according to either revised RECIST criteria or outcome measures for MMP; IVIG, intravenous immunoglobulins

jd_v_16036_f1.png